Abstract
Aim: To clinically validate the 40-gene expression profile (40-GEP) test for cutaneous squamous cell carcinoma patients and evaluate coupling the test with individual clinicopathologic risk factor-based assessment methods. Patients & methods: In a 33-site study, primary tumors with known patient outcomes were assessed under clinical testing conditions (n = 420). The 40-GEP results were integrated with clinicopathologic risk factors. Kaplan-Meier and Cox regression analyses were performed for metastasis. Results: The 40-GEP test demonstrated significant prognostic value. Risk classification was improved via integration of 40-GEP results with clinicopathologic risk factor-based assessment, with metastasis rates near the general cutaneous squamous cell carcinoma population for class 1 and ≥50% for class 2B. Conclusion: Combining molecular profiling with clinicopathologic risk factor assessment enhances stratification of cutaneous squamous cell carcinoma patients and may inform decision-making for risk-appropriate management strategies.
Original language | English (US) |
---|---|
Pages (from-to) | 833-847 |
Number of pages | 15 |
Journal | Future Oncology |
Volume | 18 |
Issue number | 7 |
DOIs | |
State | Published - Mar 2022 |
Keywords
- clinicopathologic risk factors
- cutaneous squamous cell carcinoma
- gene expression profile
- informed decision-making
- metastasis/metastatic risk
ASJC Scopus subject areas
- Oncology
- Cancer Research